Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at firstname.lastname@example.org. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
Vaxfectin-based malaria vaccine could stop transmission
An experimental malaria vaccine could prevent the transmission of malaria from mosquitoes to humans.
Finnish researchers found that the chance of narcolepsy was much higher in children who received a certain flu vaccine.
A new oral vaccine from Australia could help to cut deaths from rotavirus infections, in the developing as well as the developed world.
There is currently no chlamydia vaccine, but an Indiana University researcher has been given $2.3 million to try to create one.
ImmunoCellular Therapeutics' vaccine, ICT-140, is a cell-based vaccine in early development for the treatment of ovarian cancer.
TB vaccine in South African trials; blueprint will drive development
A new TB vaccine is expected to complete the first advanced clinical trials in South Africa in 2013.
iBio's shares have jumped 21% with the announcement that it has completed the first Phase I clinical trial of its plant-based vaccine for H1N1 influenza.
It seems that the prolonged whooping cough epidemic that's swept Australia is caused by a new strain that is evading the protection given by the vaccine.
GlaxoSmithKline has announced that it intends to invest more than £500 million ($794 million) and create up to 1,000 jobs in vaccine and pharmaceutical manufacturing in the U.K.
The name of the vesicular stomatitis virus doesn't exactly trip off the tongue, but it could be playing a major role in the treatment of melanoma by helping immune systems fight melanoma from within, if early-stage research at the Mayo Clinic comes to fruition.